TamRx, a cancer immunotherapy firm, was launched jointly by BioMotiv and Rutgers University on Thursday to advance its experimental pan-TAM inhibitors candidate to clinical trial stage by 2021. The startup plans to evaluate the efficacy of its inhibitors when combined with checkpoint inhibitors as well as other immunotherapies for an assortment of cancers.